MENU
+Compare
LABU
ETF ticker: NYSE ARCA
AS OF
Feb 3 closing price
Price
$177.31
Change
+$65.29 (+58.28%)
Net Assets
616.77M

LABU stock forecast, quote, news & analysis

The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Biotechnology Select Industry Index ("index")... Show more

Category: #Trading
LABU
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
A.I.Advisor
a Summary for LABU with price predictions
Feb 02, 2026

LABU's RSI Indicator recovers from overbought zone

The 10-day RSI Indicator for LABU moved out of overbought territory on January 23, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 instances where the indicator moved out of the overbought zone. In of the 23 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 61 cases where LABU's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for LABU turned negative on January 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LABU declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

LABU broke above its upper Bollinger Band on January 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on February 02, 2026. You may want to consider a long position or call options on LABU as a result. In of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where LABU advanced for three days, in of 303 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 197 cases where LABU Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exact Sciences Corp (NASDAQ:EXAS), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Biotechnology Select Industry Index ("index"). The fund, under normal circumstances, invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards ("GICS"). The fund is non-diversified.

Market Cap

The average market capitalization across the Direxion Daily S&P Biotech Bull 3X ETF ETF is 11.32B. The market cap for tickers in the group ranges from 61.96M to 398.83B. ABBV holds the highest valuation in this group at 398.83B. The lowest valued company is SCLX at 61.96M.

High and low price notable news

The average weekly price growth across all stocks in the Direxion Daily S&P Biotech Bull 3X ETF ETF was -3%. For the same ETF, the average monthly price growth was 13%, and the average quarterly price growth was 197%. STOK experienced the highest price growth at 15%, while NVAX experienced the biggest fall at -15%.

Volume

The average weekly volume growth across all stocks in the Direxion Daily S&P Biotech Bull 3X ETF ETF was -1%. For the same stocks of the ETF, the average monthly volume growth was -4% and the average quarterly volume growth was -20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 77
Price Growth Rating: 49
SMR Rating: 86
Profit Risk Rating: 81
Seasonality Score: -25 (-100 ... +100)
View a ticker or compare two or three
LABU
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Fundamentals
Details
Category
Trading--Leveraged Equity
Address
Direxion Shares ETF Trust33 Whitehall Street,10th FloorNew York
Phone
866-476-7523
Web
http://www.direxioninvestments.com/